Italia markets open in 7 hours 9 minutes
Dow Jones
38.225,66 +322,37 (+0,85%) Nasdaq
15.840,96 +235,48 (+1,51%) Nikkei 225
38.236,07 -37,98 (-0,10%) EUR/USD
1,0733 +0,0006 (+0,05%) Bitcoin EUR
55.110,41 +751,77 (+1,38%) CMC Crypto 200
1.275,53 +4,79 (+0,38%)
Sun Pharmaceutical Industries Limited (SUNPHARMA.NS)
NSE - NSE Prezzo in tempo reale. Valuta in INR.
Aggiungi a watchlist
Alla chiusura: 03:29PM IST
| Chiusura precedente | 1.502,10 |
| Aperto | 1.503,00 |
| Denaro | 0,00 x 0 |
| Lettera | 0,00 x 0 |
| Min-Max giorno | 1.502,00 - 1.530,00 |
| Intervallo di 52 settimane | 922,45 - 1.638,85 |
| Volume | |
| Media Volume | 2.748.223 |
| Capitalizzazione | 3,645T |
| Beta (5 anni mensile) | 0,53 |
| Rapporto PE (ttm) | 40,94 |
| EPS (ttm) | 37,10 |
| Prossima data utili | 24 mag 2024 - 28 mag 2024 |
| Rendimento e dividendo (futuro) | 12,50 (0,83%) |
| Data ex dividendo | 09 feb 2024 |
| Stima target 1A | 829,22 |
GlobeNewswireNidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma
Intratumoral Nidlegy™ followed by surgery significantly improved the Recurrence-Free Survival compared to surgery alone PIVOTAL (NCT02938299) is the first and so far only Phase III trial demonstrating statistically significant and clinically meaningful benefit of a neoadjuvant therapy in fully resectable locally advanced melanoma patients Nidlegy™ is the first immunocytokine product to show positive data in a Phase III randomized clinical trial The results will be presented at an upcoming intern
© 2024 Yahoo. Tutti i diritti riservati.